ReviewExploration of targeted anti-tumor therapy2024

Combination of the PARPi and ARSi in advanced castration resistant prostate cancer: a review of the recent phase III trials.

Martina Panebianco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.